Zenagamtide

[ghreid]

Does anyone here have firsthand experience with this peptide? I haven't come across it in any vendor catalogs, though I understand compounding pharmacies have begun producing it. It works through activity at glucagon-like peptide-1 (GLP-1), amylin, and calcitonin receptors, which helps manage appetite, delay digestion, and enhance blood sugar control.

 

[woundcarping]

So Sema-Cagri, then?

A fix hunting for something to fix.

 

[rkl123]

woundcarping said:

So Sema-Cagri, then?

A fix hunting for something to fix.

1. A limited group of people simply don't respond to these drugs. They can inject tirz and see zero effect (perhaps the immune system mounts a response against it? That remains unknown). Because of that, having additional choices is a positive thing.

2. It creates competition outside the gray market. At present, EL holds far too much power.

3. Tolerability problems still exist with the GLP's we already have. A new compound like XYZ could turn out to cause fewer side effects while delivering similar potency. Or research might show it preserves muscle tissue more effectively. Even if we never end up purchasing them, every one of these new compounds deserves to be welcomed.

 

[woundcarping]

Zenagamtide comes from Novo Nordisk. It isn't Cagrisema — that one pairs two molecules together, whereas this is a single molecule. That distinction may alter its behavior.


https://pubmed.ncbi.nlm.nih.gov/42532080/

rkl123 said:

1. A limited group of people simply don't respond to these drugs. They can inject tirz and see zero effect (perhaps the immune system mounts a response against it? That remains unknown). Because of that, having additional choices is a positive thing.

2. It creates competition outside the gray market. At present, EL holds far too much power.

3. Tolerability problems still exist with the GLP's we already have. A new compound like XYZ could turn out to cause fewer side effects while delivering similar potency. Or research might show it preserves muscle tissue more effectively. Even if we never end up purchasing them, every one of these new compounds deserves to be welcomed.

Cagrisema is a Novo product, not something from Eli Lilly.

For the most part Cagrisema has been a letdown: plenty of side effects and only a small amount of efficacy you can actually attribute to it. EL currently holds the upper hand since their offerings are clearly superior.

Cheering for something merely because it's new doesn't really move things forward. Sticking two dated peptides together to get more sides rather than more efficacy isn't worth celebrating — it's just noise. Maybe Zenagamtide will turn out differently, but the early data don't look very encouraging. I've got nothing against the effort, but expecting anything new to automatically earn a seat at the table is a real stretch.

The fact that Zenagamtide also acts as a calcitonin agonist is odd, given that research indicates calcitonin contributes little to weightless and mainly adds to adverse sides. Cag is a dual agonist, whereas that troublesome Eloralintide from EL is purely amylin.

In all fairness, I've used Sema, Tirz, Reta, and Elora, though not Cag, so I can't give a personal account of its supposedly brutish character next to how smooth Elora is. Based on what I've observed, Cag looks closer to Sema's hammer-style approach.